期刊论文详细信息
Journal of Neuroinflammation
Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF
William A Banks2  Melissa A Fleegal-DeMotta1  Shinya Dohgu3 
[1] Biology Department, Clarke University, Dubuque, IA, USA;Division of Gerontology and Geriatric Medicine, Department of Internal Medicine, University of Washington, Seattle, WA, USA;Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA
关键词: Mitogen-activated protein kinase;    Granulocyte-macrophage colony-stimulating factor;    Interleukin-6;    Lipopolysaccharide;    Human immunodeficiency virus type 1;    Blood-brain barrier;   
Others  :  1212984
DOI  :  10.1186/1742-2094-8-167
 received in 2011-08-18, accepted in 2011-11-30,  发布年份 2011
PDF
【 摘 要 】

Elevated levels of cytokines/chemokines contribute to increased neuroinvasion of human immunodeficiency virus type 1 (HIV-1). Previous work showed that lipopolysaccharide (LPS), which is present in the plasma of patients with HIV-1, enhanced transcellular transport of HIV-1 across the blood-brain barrier (BBB) through the activation of p38 mitogen-activated protein kinase (MAPK) signaling in brain microvascular endothelial cells (BMECs). Here, we found that LPS (100 μg/mL, 4 hr) selectively increased interleukin (IL)-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) release from BMECs. The enhancement of HIV-1 transport induced by luminal LPS was neutralized by treatment with luminal, but not with abluminal, antibodies to IL-6 and GM-CSF without affecting paracellular permeability as measured by transendothelial electrical resistance (TEER). Luminal, but not abluminal, IL-6 or GM-CSF also increased HIV-1 transport. U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF. These results show that p44/42 and p38 MAPK signaling pathways mediate the LPS-enhanced release of IL-6 and GM-CSF. These cytokines, in turn, act at the luminal surface of the BMEC to enhance the transcellular transport of HIV-1 independently of actions on paracellular permeability.

【 授权许可】

   
2011 Dohgu et al; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150614112254509.pdf 1211KB PDF download
Figure 7. 38KB Image download
Figure 6. 79KB Image download
Figure 5. 40KB Image download
Figure 4. 41KB Image download
Figure 3. 52KB Image download
Figure 2. 55KB Image download
Figure 1. 67KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nature Rev Immunol 2005, 5:69-81.
  • [2]McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N: Human immunodeficiency virus-associated dementia: An evolving disease. J Neurovirol 2003, 9:205-221.
  • [3]Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Geisslen M: HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. Journal of Infectious Diseases 2010, 202:1768-1769.
  • [4]Banks WA, Akerstrom V, Kastin AJ: Adsorptive endocytosis mediates the passage of HIV-1 across the blood-brain barrier: evidence for a post-internalization coreceptor. Journal of Cell Science 1998, 111:533-540.
  • [5]Banks WA, Freed EO, Wolf KM, Robinson SM, Franko M, Kumar VB: Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. Journal of Virology 2001, 75:4681-4691.
  • [6]Banks WA, Robinson SM, Wolf KM, Bess JW Jr, Arthur LO: Binding, internalization, and membrane incorporation of human immunodeficiency virus-1 at the blood-brain barrier is differentially regulated. Neuroscience 2004, 128:143-153.
  • [7]Nakaoke R, Ryerse JS, Niwa M, Banks WA: Human immunodeficiency virus type 1 transport across the in vitro mouse brain endothelial cell monolayer. Experimental Neurology 2005, 193:101-109.
  • [8]Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M: A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. The Journal of Immunology 1997, 158:3499-3510.
  • [9]Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, et al.: Human immunodeficiency virus type I enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. Journal of Virology 2002, 76:6689-6700.
  • [10]Moses AV, Bloom FE, Pauza CD, Nelson JA: Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proceedings of the National Academy of Sciences USA 1993, 90:10474-10478.
  • [11]Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA: Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
  • [12]Alonso K, Pontiggia P, Medenica R, Rizzo R: Cytokine patterns in adults with AIDS. ImmunolInvest 1997, 26:341-350.
  • [13]Gartner S: HIV infection and dementia. Science 2000, 287:602-604.
  • [14]Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A: Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 1998, 26:100-103.
  • [15]Fiala M, Looney DJ, Stins M, Way DD, Zhang L, Gan X, Chiappelli F, Schweitzer ES, Shapshak P, Weinand M, et al.: TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Molecular Medicine 1997, 3:553-564.
  • [16]Chaudhuri A, Duan F, Morsey B, Persidsky Y, Kanmogne GD: HIV-1 activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of blood-brain barrier dysfunction. J Cereb Blood Flow Metab 2007, 28:697-711.
  • [17]Kanmogne GD, Primeaux C, Grammas P: HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permability: implications for the pathogenesis of HIV-associated dementia. Journal of Neuropathology and Experimental Neurology 2005, 64:498-505.
  • [18]Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M: HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. Journal of Neuroscience Research 2003, 74:255-265.
  • [19]Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, Toborek M: HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Molecular and Cellular Neurosciences 2003, 24:224-237.
  • [20]Andras I, Pu H, Tian J, Deli MA, Nath A, Hennig B, Toborek M: Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 2005, 25:1159-1170.
  • [21]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV injection. Nature Medicine 2006, 12:1365-1371.
  • [22]Blanchard A, Montagnier L, Gougeon ML: Influence of microbial infections on the progression of HIV disease. Trends Microbiol 1997, 5:326-331.
  • [23]Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA, Cerami A, Shires GT, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1998, 166:147-153.
  • [24]Martich GD, Boujoukos AJ, Suffredini AF: Response of man to endotoxin. Immunobiology 1993, 187:403-416.
  • [25]Shalaby MR, Waage A, Aarden L, Espevik T: Endotoxin, tumor necrosis factor-alpha and interleukin-1 induce interleukin 6 production in vivo. Clin Immunol Immunopath 1989, 53:488-498.
  • [26]Banks WA, Kastin AJ, Brennan JM, Vallance KL: Adsorptive endocytosis of HIV-1 gp120 by blood-brain barrier is enhanced by lipopolysaccharide. Experimental Neurology 1999, 156:165-171.
  • [27]Singh AK, Yiang Y: How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology 2004, 201:197-207.
  • [28]Deli MA, Abraham CR, Kataoka Y, Niwa M: Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cellular and Molecular Neurobiology 2005, 25:59-127.
  • [29]Tunkel AR, Rosser SW, Hansen EJ, Scheld WM: Blood-brain barrier alterations in bacterial meningitis: development of an in vitro model and observations on the effects of lipopolysaccharide. In Vitro Cellular & Developmental Biology 1991, 27A:113-120.
  • [30]De Vries HE, Blom-Roosemalen MCM, De Boer AG, van Berkel TJ, Breimer DD, Kuiper J: Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. Journal of Pharmacology and Experimental Therapeutics 1996, 277:1418-1423.
  • [31]Descamps L, Coisne C, Dehouck B, Cecchelli R, Torpier G: Protective effect of glial cells against lipopolysaccharide-mediated blood-brain barrier injury. Glia 2003, 42:46-58.
  • [32]Boveri M, Kinsner A, Berezowski V, Lenfant AM, Draing C, Cecchelli R, Dehouck MP, Hartung T, Prieto P, Bal-Price A: Highly purified lipoteichoic acid from gram-positive bacteria induced in vitro blood-brain barrier disruption through glia activation: role of proinflammatory cytokines and nitric oxide. Neuroscience 2006, 137:1193-1209.
  • [33]Veszelka S, Pasztoi M, Farkas AE, Krizbai I, Ngo TK, Niwa M, Abraham CS, Deli MA: Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Nerurochem Int 2007, 50:219-228.
  • [34]Verma S, Nakaoke R, Dohgu S, Banks WA: Release of cytokines by brain endothelial cells: a polarized response to lipopolysaccharide. Brain, Behavior, and Immunity 2006, 20:449-455.
  • [35]Dohgu S, Banks WA: Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is medited by the p38 mitogen-activated protein kinase pathway. Experimental Neurology 2008, 210:740-749.
  • [36]Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, et al.: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. Journal of Virology 1998, 72:7992-8001.
  • [37]Frost EH: Radioactive labelling of viruses: an iodination preserving biological properties. JGenVirol 1977, 35:181-185.
  • [38]Montelaro RC, Rueckert RR: On the use of chloramine-T to iodinate specifically the surface proteins of intact enveloped viruses. JGenVirol 1975, 29:127-131.
  • [39]Szabo CA, Deli MA, Ngo TKD, Joo F: Production of pure primary rat cerebral endothelial cell culture: a comparison of different methods. Neurobiology 1997, 5:1-16.
  • [40]Perriere N, Demeuse P, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud PO, et al.: Puromycin-based purification of rat brain capillary endothelial cell cultures. J Neurochem 2005, 93:279-289.
  • [41]Dehouck MP, Jolliet-Riant P, Bree F, Fruchart JC, Cecchelli R, Tillement JP: Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models. J Neurochem 1992, 58:1790-1797.
  • [42]Waage A, Bakke O: Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988, 63:299-302.
  • [43]Hoheisel D, Nits T, Franke H, Wegener J, Hakvoort A, Tilling T, Galla HJ: Hydrocortisone reinforces the blood-brain barrier properties in a serum free cell culture system. Biochemical and Biophysical Research Communications 1998, 217:312-315.
  • [44]Mayhan WG, Heistad DD: Permeability of blood-brain barrier to various sized molecules. Am J Physiology 1985, 248:H712-H718.
  • [45]Chou S, Dix RD: Viral infections and the blood-brain barrier. In Implications of the Blood-Brain Barrier and Its Manipulation, Volume 2: Clinical Aspects. Edited by Neuwelt EA. New York: Plenum Publishing Corporation; 1989:449-468.
  • [46]Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, Tsuruo T, Sawada Y, Niwa M, Kataoka Y: Brain pericytes contribute to the upregulation and maintenance of blood-brain barrier functions through transforming growth factor-beta production. Brain Res 2005, 1038:208-215.
  • [47]Andjelkovic AV, Zochowski MR, Morgan F, Pachter JS: Qualitative and quantitative analysis of monocyte transendothelial migration by confocal microscopy and three-dimensional image reconstruction. In Vitro Cellular & Developmental BiologyAnimal 2001, 37:111-120.
  • [48]de Vries HE, Blom-Roosemalen MCM, van Oosten M, de Boer AG, van Berkel TJC, Breimer DD, Kuiper J: The influence of cytokines on the integrity of the blood-brain barrier. Journal of Neuroimmunology 1996, 64:37-43.
  • [49]Farkas G, Marton J, Nagy Z, Mandi Y, Takacs T, Deli MA, Abraham CS: Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6. Neurosci Lett 1998, 242:147-150.
  • [50]Dong C, Davis RJ, Flavell RA: MAP kinase in the immune response. Annual Review of Immunology 2002, 20:55-72.
  • [51]Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6 cytokine signaling and its regulation. Biochem J 2003, 374:1-20.
  • [52]Al-Shami A, Mahanna W, Naccache PH: Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. J Biol Chem 1998, 273:1058-1063.
  • [53]Anathbandhu C, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD: STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 2007, 111:2062-2072.
  文献评价指标  
  下载次数:184次 浏览次数:16次